Tek cümledeki fark
Both can reduce how much of a protein your body makes. CRISPR does it by changing the gene — once, permanently. RNA interference does it by destroying the working copies as they are made, which means repeating the treatment indefinitely but also being able to stop. For ATTR amyloidosis both approaches target the same gene, which makes the comparison unusually concrete.
| Boyut | CRISPR gene editing | RNA interference |
|---|---|---|
| What it changes | The gene itself | The messages made from the gene |
| Permanence | Permanent | Temporary — repeat dosing required |
| Can it be stopped? | No | Yes — stop dosing and it wears off |
| Dosing | Once | Regularly, indefinitely |
| Safety data available | A few years | Years, from approved medicines in routine use |
| Clinical status | One approved medicine | Multiple approved medicines |
| Same-target example | Nexiguran ziclumeran for ATTR | Patisiran and vutrisiran for ATTR |
Which is better?
Neither, in general. The editing approach offers one treatment instead of a lifetime of them. The RNAi approach offers years of accumulated safety data and the ability to stop if something goes wrong. For a young patient facing decades of injections, permanence looks attractive; for an older patient with other conditions, reversibility may matter more. It is the clearest illustration on this site that newer does not settle a clinical question.
Sources
- Nature (Fire et al.) · 1998
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans ↗